U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07362173) titled 'Actualities in Procedural Sedation: Remimazolam' on July 04, 2025.
Brief Summary: Remimazolam is a new, ultra-short-acting benzodiazepine approved in Romania for procedural sedation. It shows significant clinical benefits compared to other sedatives like Propofol or Midazolam, especially in elderly or high-risk patients. Advantages include better hemodynamic stability, reduced respiratory depression, lower incidence of postoperative delirium, and rapid recovery without residual sedation. It is metabolized by liver esterases and is less affected by organ dysfunction. Clinical studies suggest that remimazolam may be a safer and more e...